• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antiplatelet Treatment With Dual Pathway Inhibition: A Pathway of Consistency?

作者信息

Geisler Tobias

机构信息

Department of Cardiology and Angiology, University Hospital Tübingen Tübingen, Germany.

出版信息

Eur Cardiol. 2024 Jul 1;19:e11. doi: 10.15420/ecr.2023.52. eCollection 2024.

DOI:10.15420/ecr.2023.52
PMID:39081483
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11287618/
Abstract
摘要

相似文献

1
Antiplatelet Treatment With Dual Pathway Inhibition: A Pathway of Consistency?双途径抑制的抗血小板治疗：一条连贯的途径？
Eur Cardiol. 2024 Jul 1;19:e11. doi: 10.15420/ecr.2023.52. eCollection 2024.
2
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.在血管剂量的利伐沙班或阿司匹林基础上加用血小板P2Y12抑制治疗：双途径抑制与双重抗血小板治疗的药效学研究
Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29;8(7):728-737. doi: 10.1093/ehjcvp/pvac022.
3
Dual antiplatelet therapy is associated with high α-tubulin acetylation in circulating platelets from coronary artery disease patients.双联抗血小板治疗与冠心病患者循环血小板中α-微管蛋白乙酰化水平升高有关。
Platelets. 2023 Dec;34(1):2250002. doi: 10.1080/09537104.2023.2250002.
4
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study.利伐沙班联合阿司匹林用于心血管疾病患者的缺血性事件预防：一项成本效益研究。
Eur J Prev Cardiol. 2020 Sep;27(13):1354-1365. doi: 10.1177/2047487320913380. Epub 2020 Mar 29.
5
Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.多不饱和ω-3 脂肪酸对经皮冠状动脉介入治疗患者双联抗血小板治疗反应性的影响：OMEGA-PCI 研究（经皮冠状动脉介入治疗后ω-3 脂肪酸改变双联抗血小板治疗反应性研究）。
J Am Coll Cardiol. 2010 Apr 20;55(16):1671-8. doi: 10.1016/j.jacc.2009.11.080.
6
Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.西洛他唑三联抗血小板治疗与标准双联抗血小板治疗在接受冠状动脉介入治疗患者中的治疗期血小板反应性比较：一项荟萃分析。
J Cardiovasc Pharmacol Ther. 2013 Nov;18(6):533-43. doi: 10.1177/1074248413495971. Epub 2013 Jul 19.
7
Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials.双重途径抑制在心血管疾病患者中的疗效和安全性：来自 7 项随机试验的 49802 例患者的荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2022 Aug 11;8(5):519-528. doi: 10.1093/ehjcvp/pvab043.
8
Efficacy of cilostazol-based dual antiplatelet treatment in patients undergoing carotid artery stenting.西洛他唑双重抗血小板治疗在接受颈动脉支架置入术患者中的疗效
Neurol Res. 2017 Aug;39(8):695-701. doi: 10.1080/01616412.2017.1301042. Epub 2017 Mar 14.
9
Prasugrel Single Antiplatelet Therapy versus Aspirin and Clopidogrel Dual Antiplatelet Therapy for Flow Diverter Treatment for Cerebral Aneurysms: A Retrospective Multicenter Study.血流导向装置治疗颅内动脉瘤时普拉格雷单抗血小板治疗与阿司匹林和氯吡格雷双联抗血小板治疗的比较：一项回顾性多中心研究。
AJNR Am J Neuroradiol. 2024 May 9;45(5):592-598. doi: 10.3174/ajnr.A8163.
10
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.细胞色素P450 2C19功能缺失多态性而非CYP3A4 IVS10 + 12G/A和P2Y12 T744C多态性与高危血管疾病患者双联抗血小板治疗反应的变异性相关。
Pharmacogenet Genomics. 2007 Dec;17(12):1057-64. doi: 10.1097/FPC.0b013e3282f1b2be.

本文引用的文献

1
Dual-pathway Inhibition with Low-dose Aspirin and Rivaroxaban versus Aspirin Monotherapy in Patients with Coronary Artery Disease and Peripheral Artery Disease: Systematic Literature Review and Meta-analysis.低剂量阿司匹林与利伐沙班双途径抑制对比阿司匹林单药治疗冠心病和外周动脉疾病患者：系统文献综述与荟萃分析
Eur Cardiol. 2023 Apr 5;19:e01. doi: 10.15420/ecr.2023.40. eCollection 2024.
2
Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials.双重途径抑制在心血管疾病患者中的疗效和安全性：来自 7 项随机试验的 49802 例患者的荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2022 Aug 11;8(5):519-528. doi: 10.1093/ehjcvp/pvab043.
3
Rivaroxaban in Peripheral Artery Disease after Revascularization.利伐沙班治疗血管重建术后外周动脉疾病
N Engl J Med. 2020 May 21;382(21):1994-2004. doi: 10.1056/NEJMoa2000052. Epub 2020 Mar 28.
4
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.利伐沙班联合或不联合阿司匹林用于心力衰竭合并慢性冠状动脉或外周动脉疾病患者
Circulation. 2019 Aug 13;140(7):529-537. doi: 10.1161/CIRCULATIONAHA.119.039609. Epub 2019 Jun 5.
5
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.利伐沙班治疗心力衰竭伴窦性节律和冠心病患者的疗效。
N Engl J Med. 2018 Oct 4;379(14):1332-1342. doi: 10.1056/NEJMoa1808848. Epub 2018 Aug 27.
6
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.利伐沙班联合或不联合阿司匹林治疗稳定的外周动脉或颈动脉疾病患者：一项国际、随机、双盲、安慰剂对照试验。
Lancet. 2018 Jan 20;391(10117):219-229. doi: 10.1016/S0140-6736(17)32409-1. Epub 2017 Nov 10.
7
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.利伐沙班联合或不联合阿司匹林用于稳定性冠心病患者：一项国际、随机、双盲、安慰剂对照试验。
Lancet. 2018 Jan 20;391(10117):205-218. doi: 10.1016/S0140-6736(17)32458-3. Epub 2017 Nov 10.
8
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.利伐沙班联合或不联合阿司匹林用于稳定型心血管疾病。
N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.
9
Rivaroxaban in patients with a recent acute coronary syndrome.利伐沙班用于近期急性冠状动脉综合征患者。
N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13.
10
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.利伐沙班与安慰剂用于急性冠脉综合征患者的疗效对比（ATLAS ACS-TIMI 46）：一项随机、双盲、II期试验
Lancet. 2009 Jul 4;374(9683):29-38. doi: 10.1016/S0140-6736(09)60738-8. Epub 2009 Jun 17.